OTC Watch

All stocks / INTI

Inhibitor Therapeutics, Inc. INTI

Inhibitor Therapeutics (INTI): no warning signs from our rules in the last 12 months and the latest annual figures in plain language. Each fact links to its SEC filing.

Estimated float OTCQBFlorida, USA
Live quote on OTC Markets

Market listing

Full name
INHIBITOR THERAPEUTICS INC
Market tier
OTCQB
Trading status
Active
Last trade
Nov 13
Source: Stockwatch, 2026-11-17

News headlines

Inhibitor Therapeutics Highlights Key Developments and Reminds Stockholders of September 15 Annual Meeting
2026-09-08 17:16 · News Release
Inhibitor Therapeutics Provides Clinical, Formulation and IP Update on Itraconazole Program for Gorlin Syndrome
2026-03-31 15:44 · News Release
Headlines only, with links to the full item. Company press releases are written by the company.

The financial report, and what it means

Annual figures to 2025-12-31
The report says
Net loss
($3,300,337)
What it means

It spends more than it earns

Under strain

The company lost $3.3 million in the year. It reported no sales.

The report says
Cash and cash equivalents
$2,375,493
Net cash used in operating activities
($3,231,370)
What it means

The cash could run out soon

Under strain

It had $2.4 million in the bank and used about $269,281 a month. At that pace the money lasts about 9 months unless it borrows or sells more shares.

The report says
Total assets
$2,511,307
Total liabilities
$3,803,219
What it means

It owes more than it owns

Under strain

Everything the company owns adds up to $2.5 million. Its debts and unpaid bills add up to $3.8 million. That is about $1.51 owed for every $1 owned.

What this adds up to

3 of 3 checks show strain. It spends more than it earns. The cash could run out soon. It owes more than it owns. These are facts from the company's own reports, not a recommendation.

Signals

Estimated float2026-11-16

Estimated float about 127,294,701 shares as of 2026-11-16: 173,791,968 outstanding minus 46,497,267 held by 7 reporting insider(s).

Rule: Estimated: shares outstanding minus the latest holdings insiders reported on Forms 3/4/5. Holders of 5% or more (13D/13G) are not yet subtracted. Source record

Shares outstanding

Source: SEC filings
2025-12-31
172.6M
2026-03-25
172.6M
2026-03-31
172.6M
2026-05-15
172.6M
2026-06-30
173.8M
2026-08-14
173.8M
2026-09-30
173.8M
2026-11-16
173.8M

Price chart

Chart by TradingView. We do not store or publish prices. Live quote on OTC Markets

Recent filings

2026-11-16 10-Q10-Q
2026-09-18 8-K8-K
2026-08-17 DEF 14ADEF 14A
2026-08-14 10-Q10-Q
2026-08-04 44
2026-08-04 44
2026-08-04 44
2026-08-04 44
2026-08-04 44
2026-06-24 44
2026-06-01 44
2026-05-15 10-Q10-Q

Common questions about INTI

Does INTI file reports with the SEC?

Yes. Inhibitor Therapeutics files with the SEC under company number 0001042418. The most recent filing we hold is a 10-Q dated 2026-11-16.

Source record

How many INTI shares are outstanding?

173,791,968 shares as of 2026-11-16, as reported to the SEC.

Source record

Has INTI filed reports late?

We found no late-filing notices (NT 10-K or NT 10-Q) in its last 12 months of SEC filings.

Who runs Inhibitor Therapeutics?

Officers named in its insider filings: James A Mcnulty (Chief Financial Officer) and Francis E Odonnell Jr (Chief Executive Officer).

Source record

Is Inhibitor Therapeutics making money?

The company lost $3.3 million in the year. It reported no sales. (Annual figures to 2025-12-31. Facts from the company's own report, not a recommendation.)

Source record